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SARS-CoV-2 infection begins with the interaction of the SARS-CoV-2 Spike (Spike) and 
human angiotensin-converting enzyme 2 (ACE2). To explore whether population variants in 
ACE2 might influence Spike binding and hence infection, we selected 10 ACE2 variants 
based on affinity predictions and prevalence in gnomAD and measured their affinities for 
Spike receptor binding domain through surface plasmon resonance (SPR). We discovered 
variants that enhance and reduce binding, including two variants with distinct population 
distributions that enhanced affinity for Spike. ACE2 p.Ser19Pro (ΔΔG = 0.59 ± 0.08 kcal mol-
1) is often seen in the gnomAD African cohort (AF = 0.003) whilst p.Lys26Arg (ΔΔG = 0.26 ± 
0.09 kcal mol-1) is predominant in the Ashkenazi Jewish (AF = 0.01) and European non-
Finnish (AF = 0.006) cohorts. Carriers of these alleles may be more susceptible to infection 
or severe disease and these variants may influence the global epidemiology of Covid-19. We 
also identified three rare ACE2 variants that strongly inhibited (p.Glu37Lys, ΔΔG = –1.33 ± 
0.15 kcal mol-1 and p.Gly352Val, predicted ΔΔG = –1.17 kcal mol-1) or abolished 
(p.Asp355Asn) Spike binding. These variants may confer resistance to infection. Finally, we 
calibrated the mCSM-PPI2 ΔΔG prediction algorithm against our SPR data, give new 
predictions for all possible ACE2 missense variants at the Spike interface and estimate the 
overall burden of ACE2 variants on Covid-19 phenotypes. 
1 Introduction 
The COVID-19 pandemic is one of the greatest global health challenges of modern times. 
Although the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is usually cleared following mild symptoms, it can progress to serious illness and 
death1. Besides the clear risks associated with age and comorbidities2,3, there could be a 
genetic component that predisposes some individuals to worse outcomes4. Genetic 
association studies have already identified several loci involved in Covid-19 risk5. Identifying 
further genetic factors of COVID-19 susceptibility has implications for clinical decision 
making and epidemic dynamics. Genetic variation may constitute hidden risk factors and, in 
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some cases, explain why otherwise healthy individuals in low-risk groups experience severe 
disease. The identification of specific genetic variants that influence the severity and 
progression of COVID-19 presents the opportunity for predictive diagnostics, early 
intervention and personalised treatments whilst the population distribution of such variants 
could contribute to population specific risk. 
 
Human angiotensin-converting enzyme 2 (ACE2) is the host cell receptor that SARS-CoV-2 
exploits to infect human cells1,6. As this is the same receptor used by the SARS coronavirus 
(SARS-CoV) that caused the SARS outbreak in 2002, the detailed body of knowledge built 
around SARS-CoV infection is relevant to understanding SARS-CoV-21,6,7. The spike 
glycoprotein (Spike) is the coronavirus entity that recognises and binds host ACE2. Both 
SARS coronavirus Spikes include an S1 domain that contains ACE2 recognition elements and 
an S2 domain that is responsible for membrane fusion6. Spike is primed for cell fusion by 
cleavage with host furin8 and TMPRSS26, in SARS-CoV cleavage by TMPRSS2 is thought to be 
promoted upon formation of the ACE2 Spike complex9. The S1 receptor binding domains 
(RBDs) from both SARS-CoV10 and SARS-CoV-211 have been co-crystallised with human ACE2. 
The RBDs from both viruses are similar in overall architecture and interface with roughly the 
same surface on ACE2. Differences are apparent in the so-called receptor binding motif, 
which is the region of the RBD responsible for host range and specificity of coronaviruses10-
12. The binding affinity of Spike and ACE2 is known to be correlated to the infectivity of 
SARS-CoV and is determined by the complementarity of the interfaces10,12. However, 
despite its essential role in infection, risk variants in ACE2 have not been conclusively 
identified in genetic association studies. 
 
Missense variants located in protein-protein interaction interfaces can affect altered binding 
characteristics13,14 and in the context of virus-host interactions, have been shown to effect 
susceptibility15. This indicates the potential of missense variants in ACE2 to alter Spike 
binding and therefore influence a key step in SARS-CoV-2 infection. This is also suggested by 
the fact that the host range of coronaviruses is partly determined by the complementarity 
of the Spike receptor binding motif and the target hosts’ ACE2 sequence10,12. A few 
studies4,16-21 have addressed this question and gave rise to conflicting conclusions regarding 
the effects of specific variants on the interaction affinity and their relevance to the 
pandemic generally. The strongest of these used data from a published deep mutagenesis 
binding screen22 to assess the effect of ACE2 population variants on Spike affinity and 
confirmed the effects of five key variants with further biochemical assays17. In our own 
previous contribution23, we employed the mCSM-PPI2 protein-protein interaction affinity 
prediction algorithm13 to assess the effects of ACE2 variants on the binding of SARS-CoV-2 
Spike and predicted that three reported ACE2 variants would strongly inhibit or abolish 
binding (p.Asp355Asn, p.Glu37Lys and p.Gly352Val). Confidence was given to these 
predictions by the performance of mCSM-PPI213 in comparison to binding data for 26 ACE2 
mutants in complex with SARS-CoV Spike RBD12. Here we report experimental binding 
affinities of 10 ACE2 variants for isolated SARS-CoV-2 Spike RBD determined via surface 
plasmon resonance (SPR). These results give better insight into the effect of ACE2 variants 
on SARS-CoV-2 Spike binding, revealing additional variants that enhance Spike binding and 
also test the quality of our predictions. The SPR data also allowed us to recalibrate the 
mCSM-PPI2 predictions to provide more accurate estimates of the effect of interface 
variants that we did not test experimentally. 
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2.1 ACE2 variant affinities for SARS-CoV-2 Spike 
Figure 1 highlights the mutated residues on the structure of ACE211 in complex with SARS-
CoV-2 Spike. We determined the binding affinity of 10 ACE2 mutants for isolated SARS-CoV-
2 Spike RBD via surface plasmon resonance (SPR) to identify variants that may influence an 
individual’s response to infection. Nine of these mutants were selected from the 241 ACE2 
missense variants reported in gnomAD24 on the basis of our previous computational 
predictions23 and their reported prevalence, whilst the tenth mutant (p.Thr27Arg) was 
predicted to enhance Spike binding more than any other possible mutation at the interface.  
 
 
Figure 1. Binding affinity determination of ACE2 variants with SARS-CoV-2 Spike. Left: ACE2 (green) in complex with Spike 
RBD (tan) complex from biological assembly 1 derived from PDB ID: 6vw111. The positions that were mutated in this work 
are highlighted magenta. Right. The ACE2 Spike interface. Figure generated with Jalview25 and UCSF Chimera26. 
Table 1 presents experimentally determined ΔΔG and mCSM-PPI213 predictions for the 10 
ACE2 mutants together with predicted data for a further three variants, alongside variant 
population frequencies and RBD interacting residues. Our SPR data were collected in two 
batches. The first batch comprised four variants, two were predicted to strongly reduce or 
abolish Spike binding (p.Glu37Lys and p.Asp355Asn) and two predicted to enhance Spike 
binding (p.Gly326Glu and Thr27Arg)23. The SPR measurements showed strongly reduced 
binding for p.Glu37Lys and the total abolition of binding for p.Asp355Asn (within the 
concentration range assayed), in agreement with the predictions. In contrast, p.Gly326Glu 
and Thr27Arg, which had been predicted to enhance binding, displayed decreased and 
slightly decreased binding, in disagreement with the predictions. These discrepancies 
motivated a second set of SPR measurements that included six of the most prevalent ACE2 
variants close to the Spike binding site. Surprisingly, the two most common ACE2 variants 
tested bound SARS-CoV-2 Spike more strongly than reference ACE2. These were p.Lys26Arg 
(ΔΔG = 0.26 ± 0.09), which has the highest allele frequency of ACE2 variants near the Spike 
interface, and p.Ser19Pro (ΔΔG = 0.59 ± 0.09) that has the second highest frequency. Two 
other variants in this series also increased Spike binding (p.Phe40Leu and p.Pro389His) 
despite being over 8 Å from the closest Spike residue. Finally, p.Glu329Gly may cause a 
slight reduction in binding (ΔΔG = -0.09 ± 0.09) whilst p.Glu35Lys had an inhibitory effect 
(ΔΔG = -0.36 ± 0.09). These results show that ACE2 variants can both enhance and inhibit 
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Spike binding, properties that may reasonably be associated with susceptibility and 
resistance phenotypes to SARS-CoV-2 infection. 
 
Table 1. Surface plasmon resonance derived ΔΔG and mCSM-PPI213 predictions for ACE2 mutants, including gnomAD24 
missense variants, at or near the ACE2 Spike interface. See Supplementary Table 1 for mCSM-PPI2 predictions for all 
gnomAD variants in the ACE2 ectodomain. 
Mutation Distance 
to Spike 




SPR ΔΔG Max. prevalence 
(1 sf) 
p.Ser19Pro 2.6 A475,G476,S477 −0.2 0.2 0.59 ± 0.09 0.003 (AFR) 
p.Lys26Arg 6.0 (F456) 0.0 0.4 0.26 ± 0.09 0.006 (NFE) 
p.Thr27Ala 3.7 A475,N487,F456,Y473,Y489 −0.6 −0.4 - 0.00007 (AMR) 
p.Thr27Arga 3.7 “ “ 1.4 NA –0.11 ± 0.10 NA 
p.Glu35Lys 2.9 Q493 −0.5 –0.3 –0.36 ± 0.09 0.0001 (EAS) 
p.Glu37Lys 3.2 Y505 −1.2 –1.3 –1.33 ± 0.18 0.0003 (FIN) 
p.Phe40Leu 8.6 (Y449,Q498) -0.3 0.0 0.11 ± 0.09 a0.0001 (AMR) 
b0.0002 (AFR) 
p.Met82Ile 3.5 F486 −0.3 0.1 - 0.0003 (AFR) 
p.Gly326Glu 5.5 (V503,N506) 1.0 NA –0.65 ± 0.14 0.0001 (AFR) 
p.Glu329Gly 4.1 R439 −0.4 –0.1 –0.09 ± 0.09 0.0001 (NFE) 
p.Gly352Val 5.4 (Y505) −1.1 –1.2 - 0.00005 (NFE) 
p.Asp355Asn 3.5 G502,T500 −1.3 –1.5 (< –3.16 ± 0.14)b 0.00003 (NFE) 
p.Pro389His 8.1 (Y505) -0.1 0.4 0.27 ± 0.09 0.0002 (AMR) 
Column legend – Distance to Spike: The minimum distance of the wild-type residue to the SARS-CoV-2 Spike as resolved in PDB 6vw111. 
Spike residues: Spike residues within 5 angstrom of mutant site (or closest if no residues are in this range). mCSM-PPI2 ΔΔG: The predicted 
ΔΔG in kcal mol-1 for the missense mutation calculated by mCSM-PPI213 with PDB 6vw1 as the model structure. Recalibrated mCSM-PPI2 
ΔΔG: adjusted mCSM-PPI2 ΔΔG following recalibration with SPR data (§2.4). SPR ΔΔG: ΔΔG determined by SPR assay. Max. prevalence: The 
allele frequency for the gnomAD continental population with the highest frequency (see Table 4 for all population frequencies and 
definitions of all gnomAD cohort abbreviations). a. p.Thr27Arg was not reported in gnomAD and was selected as it had the highest 
predicted increased ΔΔG of any possible ACE2 mutation at the Spike interface. b. No binding was observed for ACE2 p.Asp355Asn, this 
value corresponds to the calculated maximum affinity that is consistent with this observation. 
 
2.2 Structural features of affinity modifying variants 
Figure 2 and Figure 3 illustrate the mCSM-PPI2 provided models of p.Ser19Pro and 
p.Lys26Arg. p.Lys26Arg was not predicted to make any new well-defined contacts with Spike 
residues but it is predicted to adopt a conformation that extends toward Spike residues 
Y473 and F456, coming within 7.8 Å and 6.1 Å of these residues’ aromatic rings, 
respectively, slightly beyond typical amino-aromatic interaction distances27 but potentially 
favourable when dynamics are considered. Similarly, p.Ser19Pro also does not introduce any 
new Spike contacts according to the mCSM-PPI2 model and so the enhanced affinity is 
difficult to explain but it is has been suggested that the Pro mutant stabilises the helix to 
favour Spike interaction22. ACE2 p.Ser19Pro is of further interest because of its proximity to 
Spike Ser477, which has mutated to Asn in circulating SARS-CoV-2 strains and these ACE2 
and RBD variants have been found to interact28. The mCSM-PPI2 structural models of the 
p.Asp355Asn, p.Glu37Lys and p.Gly352Val were discussed in detail in our previous work23. In 
summary, p.Asp355Asn was predicted to introduce a number of steric clashes at the 
interface, whilst p.Glu37Lys abolished an H-bond between ACE2 Glu37 and RBD Tyr505. 
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Figure 2. The structure of ACE2 (green) gnomAD24 missense variant p.Ser19Pro that enhances Spike (light blue) binding 
affinity. A. The environment of ACE2 Ser19 from PDB ID: 6vw111. B. Model of ACE2 p.Ser19Pro in complex with Spike. The 
mutant structure was modelled onto 6vw1 with mCSM-PPI13. Figure created with PyMol29. 
 
Figure 3. The structure of ACE2 (green) gnomAD24 missense variant p.Lys26Arg that enhances Spike (light blue) binding 
affinity. A. The environment of ACE2 Lys26 from PDB ID: 6vw111. B. Model of ACE2 p.Lys26Arg in complex with Spike. The 
mutant structure was modelled onto 6vw1 with mCSM-PPI13. Figure created with PyMol29. 
2.3 Enhanced Spike binding ACE2 variants are relatively common in European 
(p.Lys26Arg) and African/African-American (p.Ser19Pro) populations 
The enhanced binding by p.Lys26Arg and p.Ser19Pro is particularly interesting since this 
may effect carrier susceptibility or vulnerability toward SARS-CoV-2 infection and they have 
relatively high prevalence in the gnomAD24 populations. p.Lys26Arg is the most common 
missense variant in the ACE2 ectodomain (Total allele count = 797, Total allele frequency = 
0.004) and is predominant in the Ashkenazi Jewish cohort (ASJ AF = 0.01) and the European 
(non-Finnish) population (NFE, AF = 0.006). Amongst NFE sub-populations, it is most 
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prevalent in north-western Europeans (AF = 0.007) and least prevalent in southern 
Europeans (AF = 0.003) and Estonians (AF = 0.003). p.Lys26Arg was also observed within this 
frequency range in Latino/Admixed American (AMR, AF = 0.003) samples. The variant is less 
frequent in Finnish (FIN, AF = 0.0005), African/African-American (AFR, AF = 0.001), South 
Asian (0.001) and, especially, East Asian (0.00001) samples. Interestingly, gnomAD reports a 
second variant at this site, p.Lys26Glu, suggesting that the position is especially tolerant to 
mutation. p.Ser19Pro is the next most common ACE2 missense variant in proximity to the 
Spike binding site (AC = 64, AF = 0.0003) and has the highest positive ΔΔG of all those tested 
(ΔΔG = 0.59 ± 0.03). This variant is practically unique to the African/African-American 
gnomAD population (AFR, AC = 63, AF = 0.003). The only other observation of this variant in 
gnomAD is in a single heterozygote in the labelled “Other” cohort. As a result of these 
distinct population distributions, it is possible that these variants could contribute to some 
of the observed epidemiological30 variation between populations and ethnic groups. 
 
Given the prevalence of these variants we checked for their occurrence in recent GWAS 
studies on Covid-19 related phenotypes. Table 2 presents GWAS association results for ACE2 
p.Lys26Arg from the Covid-19 Host Genetics Initiative (HGI)31. These data show some 
consistency with the hypothesis that p.Lys26Arg contributes additional risk for more severe 
Covid outcomes, whilst not affecting the likelihood of infection. In the very severe 
respiratory confirmed Covid vs. population contrast (study A2), a non-statistically significant 
increased risk was reported (β = 0.38 ± 0.24, p = 0.12, p-het = 0.74). Other Covid HGI data 
summaries for contrasts testing for alleles associated with the risk of SARS-CoV-2 infection 
suggest the variant does not play a role in infection acquisition. Covid vs. lab/self-reported 
negative (β = -0.18 ± 0.14, p = 0.21, p-het = 0.92); Covid vs. population (β = -0.03 ± 0.11, p = 
0.81, p-het = 0.65) and predicted Covid from self-reported symptoms vs. predicted or self-
reported non-Covid (β = -0.10 ± 0.24, p = 0.67, p-het = 0.08). Although none of these tests 
achieved genome wide significance, it would be worthwhile to reassess the data after 
controlling for other loci with the greatest effect sizes, sex or other appropriate 
stratifications. 
 
Table 2: Covid Host Genetics Initiative summaries for p.Lys26Arg (rs4646116). 
Covid HGI study and description Beta SE p p-het meta N meta AF N Cases N Controls 
A2 - very severe respiratory confirmed covid vs. population 0.38 0.24 0.12 0.74 35,222 0.003 2,972 284,472 
B1 - hospitalized covid vs. not hospitalized covid Variant not reported 1,389 5,879 
B2 - hospitalized covid vs. population Variant not reported 6,492 1,012,809 
C1 - covid vs. lab/self-reported negative -0.18 0.14 0.21 0.92 64,950 0.004 11,181  116,456  
C2 - covid vs. population -0.03 0.11 0.81 0.65 972,525 0.005 17,607 1,345,334 
D1 - predicted covid from self-reported symptoms vs. 
predicted or self-reported non-covid 
-0.10 0.24 0.67 0.08 10,655 0.006 1,777 18,895 
 
2.4 Recalibrated mCSM-PPI2 ΔΔG predictions 
Our SPR data provide accurate readouts of the effect of ACE2 variants on Spike binding, but 
we could not feasibly carry out experiments for all possible ACE2 mutations at the interface. 
For variants we have not studied, predictions and other high-throughput datasets can be 
useful, so long as their applicability and limitations are well-understood. In our previous 
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work23, we calibrated predictions against relative binding data for ACE2/SARS-CoV Spike, we 
now improve this by recalibrating the mCSM-PPI2 predictions with our ACE2/SARS-CoV-2 
Spike SPR dataset. 
 
Figure 4 compares experimental and mCSM-PPI213 predicted ΔΔG. The eight mutants with 
predicted ΔΔG < 0 kcal mol-1 are linearly correlated with the experimental ΔΔG (R2 = 0.91, p 
= 0.0006), whilst the two mutants with predicted ΔΔG > 1 kcal mol-1 (p.Gly326Glu and 
Thr27Arg) do not follow this behaviour. The absence of detectable binding for p.Asp355Asn 
and the strongly reduced binding observed for p.Glu37Lys, support our original 
determination that predicted ΔΔG < –1 kcal mol-1 was a reliable indicator of inhibitory 
variants. The difficulty mCSM-PPI2 has with affinity enhancing variants is not altogether 
surprising since our original calibration showed poorer performance for these variants23, 
which may be because there were fewer experimentally determined affinity enhancing 
variants in the algorithm’s training data. Structurally, although the mCSM-PPI2 model of 
p.Gly326Glu predicted new contacts with Spike23, it is possible that reduced torsional 
flexibility at mutant Glu326 has other effects that were not recognised (a similar argument 
applies for p.Ser19Pro but here the error is small). The subtler affinity changes measured for 
the five variants with predicted ΔΔG between −0.5 and 0.0 kcal mol-1, validate our original 
ambiguity towards those predictions, but the strong linear correlation within this narrow 
range is encouraging. Taken together, these observations suggest that predictions within 
the range of p.Glu36Lys (ΔΔGpred = −1.2 kcal mol-1) and p.Lys26Arg (ΔΔGpred = 0.0 kcal mol-1) 
may be rescaled to provide a better estimate of actual ΔΔG. Recalibrated ΔΔG yields correct 
predictions for all eight mutations with negative predicted ΔΔG and measurable ΔΔG from 
SPR (Table 1). This lends additional confidence in our prediction that ACE2 p.Gly352Val 




Figure 4. Comparison of SPR ΔΔG with the mCSM-PPI2 prediction for 9 ACE2 mutations. The linear regression was fit to the 
eight ACE2 mutants with predicted ΔΔG < 0 kcal mol-1 (slope = 1.56, intercept = 0.52, R2 = 0.91, p = 0.0006). The shaded 
area indicates the 95 % confidence interval for predicted SPR ΔΔG from the linear model. Figure generated with R ggplot2. 
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2.5 Predicted burden of rare ACE2 variants with Spike affinity phenotypes 
Existing human variation datasets are well-powered to detect common variation (1KG was 
estimated to detect >99% SNPs with MAF >1%32 and gnomAD is substantially larger) in the 
sampled populations but they are far from comprehensive with respect to rare variation24. 
Rare variants in ACE2 that influence Spike binding could have implications for the 
epidemiology of COVID-19 in addition to the consequences for affected individuals. If there 
were 10 such variants with an allele frequency of 1 in 50,000, their collective occurrence 
might be as high as 1 in 5,000 (discounting linkage) and when this is considered alongside 
the possibility that a high proportion of the global population will be exposed to SARS-CoV-2 
it becomes clear that such effects should be investigated. These variants could even be 
present at significant frequencies in populations missing or underrepresented in gnomAD. 
 
Figure 5 illustrates the distribution of recalibrated mCSM-PPI2 ΔΔG predictions (ΔΔGrecal) for 
all 475 possible ACE2 mutations at 25 ACE2 residues close to the Spike interface and the 
subset that are accessible via a single base change of the ACE2 coding sequence (these are 
more likely to be present in human populations than those requiring multiple substitutions). 
Most of these mutations are predicted to have only a slight effect on Spike binding, but 
there is a secondary mode below −1.0 kcal mol-1 with 126 mutations predicted to lead to 
strongly reduced binding. Fewer variants received high positive ΔΔGrecal scores: 17 had 
ΔΔGrecal > 1.0 kcal mol-1, a further 44 had ΔΔGrecal > 0.5 kcal mol-1 and an additional 70 had 
ΔΔGrecal > 0.2 kcal mol-1 (i.e., ΔΔGrecal > p.Lys26Arg). A similar pattern is observed for the 151 
mutants corresponding to 172 single nucleotide variants of the ACE2 coding sequence 
(Figure 5B). These results suggest that random novel ACE2 missense variants at these loci 
can inhibit or enhance Spike binding, but are slightly more likely to be inhibitory, meaning 
that diversity at these positions might typically be beneficial and provide some resistance to 
infection. Notably, these recalibrated predictions do not display the same bias toward 
negative ΔΔG that the raw mCSM-PPI2 ΔΔG predictions did23 (Supplementary Figure 1), 
which may be another indicator of the improved quality of these recalibrated predictions. 
 
Even though most of these variants are not reported in gnomAD, they may still occur within 
the populations represented, especially if they occur at frequencies that are poorly 
detected. With this in mind, we calculated allele frequencies for these mutations that are 
compatible with their absence from gnomAD (see Methods) in order to gain a better idea of 
how widespread the effects of these variants might be. 
 
Table 3 presents estimated allele frequencies for novel variants that are predicted to inhibit 
and enhance Spike binding at varying ΔΔGrecal thresholds. Upper bounds for their joint 
frequencies assuming that they occur at lower frequencies than singleton variants suggest 
frequency bounds that range 1 in 1,000 to 1 in 2,000 variants per allele for inhibitory 
variants, and 1 in 1,500 to around 1 in 5,000 for enhancer variants. A second approach, 
which takes account of the empirical detection of rare variants in ACE2, yields frequencies 
that span from 1 in 6,250 to 1 in 12,195 for inhibitory variants, and 1 in 8,333 to 1 in 37,037 
for enhancer variants. These estimates show that novel variants in ACE2 with any weak 
Spike affinity phenotype could plausibly be as common as 1 in 3,571 alleles (calculated as 
the sum of the highest inhibitor and enhancer prevalence’s), but the strongest affinity 
phenotypes are more likely to occur in frequency ranges akin to rare genetic diseases. It 
should be remembered that these values are calculated to be compatible with their absence 
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from the gnomAD dataset, but it remains possible that some or all of these variants do not 





Figure 5. A. Distribution of mCSM-PPI213 predicted ΔΔG from in silico saturation mutagenesis of the ACE2-S interface in PDB 
6vw111. A. predicted ΔΔG for 475 mutations across 25 sites on ACE2 corresponding to the 23 residues within 5 Å of SARS-
CoV-2 S plus Gly326 and Gly352. B. predicted ΔΔG for the subset of 151 mutations across these sites that are accessible via 
a single base change of the ACE2 coding sequence. 
Table 3. Estimated allele frequencies of potential novel variants in ACE2 with predicted Spike binding phenotypes. The 
estimate is calculated from the observed occurrence of rare variants in ACE2 in gnomAD24 (6.1 × 10-6) and the proportion of 












Heterozygotes / 100K Hemizygotes / 100K 
Predicted Spike inhibitory variants 
< −1.0 38 41 0.0005 8.2 10−5 16.5 8.2 
< −0.5 55 59 0.0007 0.00012 23.8 11.9 
< −0.2 77 81 0.001 0.00016 33.0 16.5 
Predicted Spike enhancer variants 
> 1.0 11 14 0.0002 2.7 10-5 5.5 2.7 
> 0.5 24 30 0.0004 6.0 10-5 11.9 6.0 
> 0.2 48 58 0.0007 0.00012 23.8 11.9 
3 Discussion and conclusion 
 
3.1 Impact of ACE2 affinity variants on SARS-CoV-2 infection 
How far can affinity modulating variants influence SARS-CoV-2 infection? For inhibitory 
variants, host range specificity and mutagenesis studies12 highlight how some receptor 
mutations can provide complete protection from infection. We identified one variant 
(p.Asp355Asn) that abolished Spike binding altogether within our detection limits and a few 
others that reduced binding to varying extents. Since these variants were observed in 
population samples, some individuals carry ACE2 variants that could confer complete 
resistance to infection. Variants that reduce but do not eliminate binding may confer a 
degree of resistance proportional to the affinity reduction, or alternatively, there may be an 
affinity threshold that toggles cellular permissivity as in other enveloped viruses33. Detailed 
infectivity experiments with relevant ACE2 variants and multiple cell types are necessary to 
answer this question definitively. 
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It is less clear what effect affinity enhancing variants have on virulence, but there are 
indications that carriers may be at greater risk of infection and severe disease. Virus 
attachment proteins in enveloped viruses require a minimum receptor affinity that is 
proportional to the receptor surface density on the target cell to enable membrane fusion33. 
If this applies to SARS-CoV-2, ACE2 variants that enhance Spike binding could increase viral 
spreading in carriers due to increased cellular tropism. Greater viral spreading is associated 
with clinical deterioration34 and could cause increased infectiousness, akin to the enhanced 
transmissibility of SARS-CoV-2 vs. SARS-CoV, which is associated with increased viral loads in 
the upper respiratory tract6,35 and also correlates with enhanced receptor affinity11. The 
importance of tuned Spike-receptor affinities in SARS-CoV-2 may be enhanced because of 
the relatively low surface density of Spike on SARS-CoV-2 virions, which may lead to a weak 
avidity effect36. Anecdotal evidence is also provided by Spike RBD mutations, such as N501Y, 
that enhance ACE2 affinity37 and are associated with increased transmissibility38. Again, 
infectivity studies are needed but here the prevalence of p.Lys26Arg and p.Ser19Pro may 
allow the observation of an effect in future Covid-19 GWAS studies. 
 
Some infectivity data for SARS-CoV-2 towards cells expressing ACE2 variants are available, 
including variants p.Ser19Pro and p.Lys26Arg16. Surprisingly, SARS-CoV-2 pseudotypes 
showed slightly decreased infectivity towards HEK293T cells expressing ACE2 p.Lys26Arg, 
and no difference compared to reference ACE2 was found for the susceptibility of cells 
expressing ACE2 p.Ser19Pro16. Although these results suggest that affinity is not directly 
proportional to infectivity in a single cell type, they do not exclude the possibility that these 
variants allow increased cellular tropism as discussed above. The same study also reported 
no effect on Spike affinity caused by these variants16, which is probably due to the low 
sensitivity of the cell based binding assay employed, since enhanced binding was also found 
in a different cell based assay22. Indeed, we are especially confident in the accuracy of our 
ΔΔG measurements since our results are consistent with published deep mutagenesis 
binding data22 (Supplementary Figure 2).  In addition, another recent report agreed with our 
findings that the common ACE2 variants p.Ser19Pro and p.Lys26Arg enhanced affinity for 
Spike whilst p.Glu37Lys inhibits binding17. 
 
Other considerations relevant to the effect of ACE2 Spike affinity variants on carriers include 
ACE2 carboxypeptidase activity39, which may be modulated by the specific binding affinity, 
the effect of hemizygosity and sex differences in Covid-19 outcomes, and the interplay of 
affinity variants and ACE2 expression levels. The importance of ACE2 expression was 
mentioned earlier but it is worth highlighting that it is known to partly determine the 
cellular specificity of SARS-CoV40 and was explored as a potential factor in COVID-19 
susceptibility and severity, including the interaction between ACE2 variants and ACE2 
stimulating drugs41. Also, heterozygotes express a proportion of ACE2 alleles whilst 
hemizygotes carry only a single ACE2 allele so that ACE2 Spike affinity variants ought to 
always show greater penetrance in hemizygotes, for better or worse. In contrast and since 
ACE2 escapes complete X-inactivation20, heterozygotes have the advantage that the more 
resistant ACE2 allele could become dominant in infected tissues due to selection over 
cellular infection cycles, gradually increasing the prevalence of the more Spike resistant 
ACE2 allele. Besides the possible benefit against infection, there could be other implications 
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for heterozygotes depending on the persistence X-inactivation bias and the nature of any 
hitchhiking alleles. 
 
3.2 Prevalence of ACE2-Spike affinity genotypes 
Table 4 presents detailed allele frequencies from gnomAD24 for the ACE2 variants 
investigated in this work. The most prevalent ACE2 variant mediated Covid-19 phenotypes 
are likely to arise from the two relatively common variants found to enhance Spike binding, 
p.Ser19Pro and p.Lys26Arg. These variants were found in 3 in 1,000 individuals in the 
gnomAD African/African-American (AFR) samples and 7 in 1,000 North Western non-Finnish 
European samples (NW-NFE), respectively. p.Lys26Arg was also observed in other 
populations, including 1 in 1,000 AFR samples, adding further burden to this cohort. The 
high affinity displayed by ACE2 p.Ser19Pro is concerning in context with the reported 
disproportionate impact of Covid-19 on black and minority ethnic groups30. Further research 
to identify the impact of these variants on SARS-CoV-2 pathogenesis should be prioritised 
with urgency and existing and future GWAS should investigate these variants more closely 
with appropriate stratifications. 
 
Table 4: Detailed prevalence data from gnomAD24 for ACE2 variants reported in Table 1. 
Variant ΔΔG (kcal mol-1) AFR AMR ASJ EAS FIN NFE SAS OTH 
p.Ser19Pro 0.59 0.003 - - - - - - 0.0002 
p.Lys26Arg 0.31 0.001 0.003 0.01 0.00007 0.0005 0.006 0.001 0.003 
p.Thr27Ala (−0.4) - 0.00007 - - - - - - 
p.Glu35Lys –0.29 - - - 0.0001 - 0.00001 - - 
p.Glu37Lys –1.25 0.0001 - - - 0.0003 - - - 
p.Phe40Leu 0.14 a0.0002 b0.0001 - - - - - - 
p.Met82Ile (0.1) 0.0003 - - - - - - - 
p.Gly326Glu –0.67 0.0001 - - - - - - - 
p.Glu329Gly –0.06 - - - - - 0.00007 - 0.0002 
p.Gly352Val (–1.2) - - - - - 0.00001 - - 
p.Asp355Asn No binding - - - - - 0.00003 - - 
p.Pro389His 0.12 - 0.0002 - - - 0.00002 - - 
Total frequency  0.0047 0.00317 0.01 0.00017 0.0008 0.00614 0.001 0.0034 
Enhancers ( ³0.1 kcal mol-1)  0.0045 0.0031 0.01 0.00007 0.0005 0.0062 0.001 0.0032 
Inhibitors (£ –0.1 kcal mol-1)  0.0002 0.00007 - 0.0001 0.0003 0.00005 - - 
AFR: African/African-American, AMR: Latino/Admixed American, ASJ: Ashkenazi Jewish, EAS: 
East Asian, FIN: Finnish, NFE: non-Finnish European, SAS: South Asian, OTH: Other 
 
The remaining gnomAD variants predicted to effect Spike binding are all very rare. The two 
other variants in our SPR series that also enhanced Spike binding have a joint frequency of 
around 3 in 10,000 in Latino/Admixed American (AMR) samples whilst amongst Spike 
inhibitory variants, p.Glu37Lys is the most prevalent occurring in 3 in 10,000 in Finnish 
samples and one additional African/African American sample. The other strongly inhibitory 
variants p.Gly352Val (predicted) and p.Asp355Asn are both doubletons observed only in 
non-Finnish Europeans, corresponding to an extremely low allele frequency of 3 in 100,000. 
Notably, the inhibitory variant p.Glu35Lys is the only variant predominant in East Asian 
samples 
 
Our analysis of the effects of all possible missense mutations at the ACE2 Spike interface 
predicts many other potential novel variants that effect the Spike interaction, but even 
though a relatively high proportion of possible variants are predicted to effect Spike binding 
(up to 62%), their collective frequency could be as little as 2.8 in 10,000. These frequencies 
are comparable to those that might be expected for variants that cause rare diseases. 
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Although these data suggest that ACE2 alleles with large positive or negative ΔΔG are 
extremely rare it is important to note that allele frequencies show significant variation even 
between large variation datasets42. Moreover, it is known that local population allele 
frequencies can vary substantially from those reported in public datasets43 and it is 
therefore possible that some populations have risk or protective mutations at higher 
frequencies. It is also worth highlighting that the substantially increased Spike affinities of 
the two most common variants tested may indicate the presence of a past selective effect 
occurring twice independently, which may increase the possibility of other higher frequency 
variants amongst populations not well represented by gnomAD. 
 
These frequencies might be useful for modellers to assess the role of rare ACE2 variants 
with Spike binding phenotypes on the epidemiology of Covid-19. For example, whether rare 
ACE2 variants that inhibit Spike binding contribute to the prevalence of asymptomatic 
carriers or if rare ACE2 variants with enhanced Spike binding can account for instances of 




In summary, we report the binding affinities of 10 ACE2 variants with SARS-CoV-2 Spike 
RBD. We found that ACE2 p.Ser19Pro and p.Lys26Arg, two of the most common ACE2 
missense variants in gnomAD24, substantially increase the affinity and are therefore possible 
risk factors for COVID-19. These variants have distinct distributions across the gnomAD 
cohorts and could therefore contribute population-specific risk. Two additional rare variants 
were identified that also enhanced Spike binding, although to a lesser extent. We confirmed 
our previous predictions that ACE2 p.Glu37Lys and p.Asp355Asn strongly inhibit Spike 
binding and are therefore potentially protective against COVID-19. We also identified two 
further rare variants that inhibited binding, including p.Gly326Glu, which we had previously 
incorrectly predicted would enhance binding. The SPR affinity data were used to recalibrate 
the mCSM-PPI213 algorithm to provide improved affinity predictions for all possible ACE2 
missense variants that interact with Spike and we estimated the prevalence of novel Spike 
affinity variants in ACE2. A key point in these burden assessments is the separate 
consideration of variants predicted to inhibit and enhance Spike affinity since these may 
have distinct phenotypes. Overall, p.Ser19Pro and p.Lys26Arg are still expected to have the 
most widespread effects, with the joint prevalence of the rare affinity variants substantially 
lower, but in all cases the possibility of higher prevalence in local or underrepresented 
populations remains and the penetrance of each variant will be a key factor. This work has 
applications in helping to prioritise experimental work into SARS-CoV-2 Spike human ACE2 
recognition; developing genetic diagnostic risk profiling for COVID-19 susceptibility and 
severity, improving detection and interpretation in future COVID-19 genetic association 
studies and in understanding SARS-CoV-2 Spike evolution and host adaptation. 
Methods 
ACE2 and RBD constructs 
The ACE2 construct was kindly provided by Ray Owens at the Oxford Protein Production 
Facility-UK. The RBD construct was kindly provided by Quentin Sattentau at the Sir William 
Dunn School of Pathology. ACE2 point mutations were added using Agilent QuikChange II XL 
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Site-Directed Mutagenesis Kit following the manufactures instructions. The primers were 
designed using the Agilent QuikChange primer design web program. 
 
HEK293F suspension cell culture 
Cells were grown in FreeStyle™ 293 Expression Medium (12338018) in a 37 °C incubator 
with 8% CO2 on a shaking platform at 130 rpm. Cells were passaged every 2-3 days with the 
suspension volume always kept below 33.3% of the total flask capacity. The cell density was 
kept between 0.5 and 2 million per ml. 
 
Transfection of HEK293F suspension cells 
Cells were counted to check cell viability was above 95% and the density adjusted to 1.0 
million per ml. For 100 ml transfection, 100 µl FreeStyle™ MAX Reagent (16447100) was 
mixed with 2 ml Opti-MEM (51985034) for 5 minutes. During this incubation 100 µg of 
expression plasmid was mixed with 2 ml Opti-MEM. For in situ biotinylation of ACE2 90 µg 
of expression plasmid was mixed with 10 µg of expression plasmid encoding the BirA 
enzyme. The DNA was then mixed with the MAX Reagent and incubated for 25 minutes 
before being added to the cell culture. For ACE2 biotinylation biotin was added to the cell 
culture at a final concentration of 50 µM. The culture was left for 5 days for protein 
expression to take place. 
 
Protein purification from HEK293F suspension cell supernatant 
Cells were harvested by centrifugation and the supernatant collected and filtered through a 
0.22 μm filter. Imidazole was added to a final concentration of 10 mM and PMSF added to a 
final concentration of 1 mM. 1 ml of Ni-NTA Agarose (30310) was added per 100 ml of 
supernatant and the mix was left on a rolling platform at 4 °C overnight. The supernatant 
mix was poured through a gravity flow column to collect the Ni-NTA Agarose. The Ni-NTA 
Agarose was washed 3 times with 25 ml of wash buffer (50 mM NaH2PO4, 300 mM NaCl 
and 20 mM imidazole at pH 8). The protein was eluted from the Ni-NTA Agarose with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl and 250 mM imidazole at pH 8). The protein 
was concentrated, and buffer exchanged into size exclusion buffer (25 mM NaH2PO4, 150 
mM NaCl at pH 7.5) using a protein concentrator with a 10,000 molecular weight cut-off. 
The protein was concentrated down to less than 500 μl before loading onto a Superdex 200 
10/300 GL size exclusion column. Fractions corresponding to the desired peak were pooled 
and frozen at -80 °C. Samples from all observed peaks were analysed on an SDS-PAGE gel 
(Supplementary Figure 3). 
 
Surface plasmon resonance (SPR) 
SARS-CoV-2 receptor binding domain binding to human extracellular ACE2 were analysed on 
a Biacore T200 instrument (GE Healthcare Life Sciences) at 37°C and a flow rate of 30 
µl/min. Running buffer was HBS-EP (BR100669). Streptavidin was coupled to a CM5 sensor 
chip (29149603) using an amine coupling kit (BR100050) to near saturation, typically 10000-
12000 response units (RU). Biotinylated ACE2 WT and variants were injected into the 
experimental flow cells (FC2–FC4) for different lengths of time to produce desired 
immobilisation levels (600–700 RU). FC1 was used as a reference and contained streptavidin 
only. Excess streptavidin was blocked with two 40 s injections of 250 µM biotin (Avidity). 
Before RBD injections, the chip surface was conditioned with 8 injections of the running 
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buffer. A dilution series of RBD was then injected simultaneously in all FCs. Buffer was 
injected after every 2 or 3 RBD injections. The lowest RBD concentration was injected at the 
beginning and at the end of each dilution series to ensure reproducibility. The length of all 
injections was 30 s, and dissociation was monitored from 180-300 s. Binding measured in 
FC1 was subtracted from the other three FCs. Additionally, all binding and dissociation data 
were double referenced using the closest buffer injections44. In all experiments, an ACE2-
specific antibody (NOVUS Biologicals, AC384) was injected at 5 µg/ml for 10 minutes with 
the disassociation monitored for 10 minutes (Supplementary Figure 4). Only ACE2 T27R did 
not bind AC384 as expected but since this mutant displays RBD binding comparable to WT 
ACE2, this most likely indicates direct inhibition of AC384 binding rather than the presence 
of unfolded protein. 
 
SPR data fitting 
Double referenced binding data was plotted and fit with GraphPad Prism (Supplementary 
Figure 5). To find the equilibrium KD (dissociation constant) the association phase was fit 
with a One−phase association model and the plateau binding measurements were extracted 
and plotted against the corresponding concentration of RBD. This plot was then fit with a 







To convert KD values to ΔG the equation below was used. Where R is the gas constant 
measured in cal mol-1 K-1 and T is the temperature measured in K. 
 
ΔG	 = 	R ∗ 	T ∗ 	ln	K! 
 
A ΔΔG value could then be found for each mutant by subtracting the ΔG of the WT from the 
ΔG of each mutant. 
 
For ACE2 variant D355N binding was too poor to fit accurately therefore, an estimate for the 
lower limit for the KD was calculated using the formula below. Where the “Maximum [RBD]” 
is the highest concentration of RBD flown over the surface, the “Binding at KD (WT)” is the 
RU value at the equilibrium KD for the WT protein on the same chip and the “Binding at 
maximum [RBD] (variant)” is the maximum RU value for the RBD binding D355N at the 
highest concentration. The estimated KD lower limit could then be converted into ΔG and 
then ΔΔG using the same method above. 
 




Integration of structure, variant and mutagenesis data 
The pyDRSASP suite45 was used to integrate 3D structure, population variant and 
mutagenesis assay data for analysis. Population variants from gnomAD v224 were mapped to 
ACE2 with VarAlign45. Residue mappings were derived from the Ensembl VEP annotations 
present in the gnomAD VCF. In addition, we manually checked the gnomAD multi nucleotide 
polymorphisms (MNPs) data file and found no records for ACE2. The structure of chimeric 
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SARS-CoV-2 Spike receptor binding domain in complex with human ACE2 (PDB ID: 6vw1)11 
was downloaded from PDBe. Residue-residue contacts were calculated with ARPEGGIO46. 
These operations were run with our ProIntVar45 Python package, which processes all these 
data into conveniently accessible Pandas DataFrames. ACE2 Spike interface residues were 
defined as those with any interprotein interatomic contact (Supplementary Table 2). 
 
Prediction of missense variant effects on Spike – ACE2 interaction 
The mCSM-PPI213 web server was used to predict the effect of mutations on the SARS-CoV-2 
Spike-ACE2 interface topology and binding affinity with the structure PDB ID: 6vw111 
according to our previous protocol23. 
 
Recalibrated mCSM-PPI2 predictions with SPR tested variants 
The SPR determined ΔΔG (Kd-plateau) were regressed against the mCSM-PPI2 prediction, 
restricting the regression to the variants with negative predicted ΔΔG, with the lm function 
in R47. Recalibrated scores were calculated with the predict.lm function and applied to ACE2 
variants within 10 angstroms of Spike. 
 
Enumerating possible ACE2 missense SNPs 
The ACE2 gene (ENSG00000130234) was retrieved from Ensembl in Jalview25. Two identical 
CDS transcripts (ENST00000427411 and ENST00000252519) were found with the Get Cross-
References command corresponding to ACE2 full-length proteins (ENSP00000389326 and 
ENSP00000252519). These correspond to the UniProt ACE2 sequence Q9BYF1. The CDS was 
saved in Fasta format and this was parsed in Python with Biopython. The CDS was broken 
into codons and all possible single base changes were enumerated and translated using the 
standard genetic code. This provided the set of amino acids accessible to each residue via a 
single base change. 
 
Estimated Prevalence of Novel Rare Variants in ACE2 with Spike Affinity Phenotypes 
Upper bound from gnomAD singleton frequency (Minimum reportable frequency) 
Upper bounds for the total prevalence of potential Spike affinity variants were calculated 
based on the conservative assumption that novel variants must occur at lower frequencies 
than the minimum reportable variant frequency (i.e., minimum singleton frequency) in 
gnomAD. The theoretical minimum reportable frequency is the allele frequency of a 
singleton variant at a site where all samples have been effectively called. For alleles on the X 
chromosome, the proportion of XX and XY samples is important since the number of alleles 
sequenced is 2𝑁#$%&'$ + 𝑁%&'$. Practically, many reported singleton frequencies are 
greater than this theoretical minimum because at a given loci not all samples have sufficient 
sequence data quality to be called. Therefore, the minimum reportable frequency varies by 
genomic position, as well as population. Since gnomAD reports the allele number (AN) only 
for variant sites, we used the maximum observed allele number in ACE2. For example, the 
maximum allele number in ACE2 corresponding to non-Finnish European samples is 80,119 
(AN_NFE = 80,119). This yields a minimum observed variant frequency in ACE2 amongst 
non-Finnish Europeans in gnomAD (v2 exomes) of 1/80,119 = 1.2 × 10-5, or 2.5 variants per 
200,000 alleles. The total prevalence is then found by multiplying this value by the number 
of SNPs being considered. 
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Empirical detection rate of rare ACE2 variants and the affinity active ratio based estimate 
Our second approach to estimate plausible frequencies of novel variants (P) was to project 
the empirical detection rate of rare ACE2 variants in gnomAD (k) onto the sites that 
correspond to the Spike interface (n), and then adjust this by the proportion of variants that 
are predicted to effect Spike binding (a) so that, 
 
𝑃 = a𝑘𝑛 
 
For example, there are 1,181 variant alleles in the 56,885 non-Finnish European cohort 
(AN_NFE = 80,119) arising from variants with AF < 0.01 in the 2,415 nucleotide ACE2 coding 
sequence (n.b. at this AF threshold, 90 % are missense). This corresponds to a variation rate 
k = 6.1 × 10-6 variants per nucleotide per allele. Projecting rate k onto the 25 ACE2 sites 
considered (n = 75 nucleotides) we find kn = 4.6 × 10-4 variants per allele, or 91.6 variants 
per 200,000 alleles. Note that this should be a conservative estimate of variability at these 
sites, since surface residues tend to be more variable than the core or other functional 
regions of the protein48, unless the site is under specific selection. The proportion of SNPs 
that are defined to have an affinity phenotype is dependent on the ΔΔGrecal threshold. For 
example, there are 38 substitutions corresponding to 41 single nucleotide variants out of 
the a possible 225 that are predicted to inhibit binding with ΔΔGrecal < −1.0 kcal mol-1 (Table 
3) so that a = 41 / 225 = 0.18. Altogether this gives P = 8.2 10−5 for variants with ΔΔGrecal < 
−1.0 kcal mol-1. This calculation could be improved (e.g., to account for missense/ 
synonymous ratios in a) but in its current form is suitable to provide estimates that indicate 
plausible orders of magnitude of these variants’ prevalence as intended. 
 
Software 
Jalview 2.1125 was used for interactive sequence data retrieval, sequence analysis, structure 
data analysis and figure generation. UCSF Chimera26 and PyMol29 were used for structure 
analysis and figure generation. 
 
The pyDRSASP45 packages, comprising ProteoFAV, ProIntVar and VarAlign were used for 
data retrieval and analysis. Biopython was used to process sequence data. 
 
Data analyses were coded in R and Python Jupyter Notebooks. Numpy, Pandas and Scipy 
were used for data analysis. Matplotlib, Seaborn and ggplot2 were used to plot data. 
Code availability 
All code and analysis notebooks used in this study are available from the Barton Group 
public GitHub repository at https://github.com/bartongroup/covid19-ace2-variants. 
Data availability 
This study employed several public datasets, which are available from their original sources 
and all necessary identifiers and accessions are provided in the methods. Data that was 
compiled and calculated as part of this study are available from the BioStudies database 
(https://www.ebi.ac.uk/biostudies) under accession S-BSST649. 
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Supplementary Table 1. mCSM-PPI2 predictions for all gnomAD ACE2 missense variants in residues resolved in PDB 6vw1. 
ID Mutation Distance to Interface mCSM-PPI2 ΔΔG Allele Count AC Male AC Popn. Max Popn. 
Max 
rs73635825 p.Ser19Pro 2.6 -0.2 40 6 39 AFR 
- p.Ile21Thr 7.3 0.3 1 1 1 AMR 
rs778030746 p.Ile21Val 7.3 -0.4 2 2 2 NFE 
rs756231991 p.Glu23Lys 6.2 -0.4 1 0 1 NFE 
rs4646116 p.Lys26Arg 6.0 0.0 704 258 85 ASJ 
- p.Lys26Glu 6.0 0.1 1 1 1 NFE 
rs781255386 p.Thr27Ala 3.7 -0.6 2 0 2 AMR 
- p.Glu35Lys 2.9 -0.5 3 1 2 EAS 
rs146676783 p.Glu37Lys 3.2 -1.2 6 3 5 FIN 
- p.Phe40Leu 8.6 -0.3 3 0 3 AMR 
- p.Ser43Arg 8.5 -0.1 1 0 1 SAS 
- p.Tyr50Phe 13.0 -0.3 1 0 1 NFE 
rs760159085 p.Asn51Asp 14.2 0.1 2 1 2 SAS 
rs775273812 p.Thr55Ala 15.3 0.0 1 1 1 NFE 
rs771621249 p.Asn58Lys 12.0 -0.3 2 0 2 SAS 
- p.Asn58His 12.0 -0.1 2 1 2 NFE 
rs759162332 p.Gln60Arg 15.5 0.1 2 0 2 NFE 
- p.Met62Val 13.5 0.0 1 1 1 NFE 
- p.Asn64Lys 13.2 0.1 1 1 1 AFR 
rs755691167 p.Lys68Glu 7.3 0.1 2 2 2 SAS 
- p.Phe72Val 8.7 -0.4 1 1 1 EAS 
- p.Ser77Phe 9.3 -0.1 1 1 1 NFE 
rs766996587 p.Met82Ile 3.5 -0.3 0 0 0 
 
rs766996587 p.Met82Ile 3.5 -0.3 2 0 2 AFR 
rs759134032 p.Pro84Thr 7.1 -0.1 1 0 1 SAS 
rs746808776 p.Gln86Arg 13.1 0.2 2 1 2 NFE 
rs763395248 p.Thr92Ile 15.1 -0.1 2 2 2 NFE 
- p.Gln102Pro 14.8 -0.2 2 0 1 NFE 
rs143158922 p.Asn103His 14.8 0.0 2 0 2 AFR 
rs139773121 p.Val107Ala 19.8 -0.1 2 1 2 AFR 
rs201900069 p.Arg115Gln 30.4 0.0 30 15 9 EAS 
rs751227277 p.Ser128Thr 28.6 -0.1 1 0 1 SAS 
rs766124365 p.Pro138Ala 45.4 -0.1 1 1 1 NFE 
- p.Cys141Tyr 38.5 0.0 1 0 1 AFR 
- p.Asn154Lys 38.4 0.0 2 0 1 AMR 
rs746034076 p.Asn159Ser 49.4 0.1 2 1 1 AMR 
- p.Ala164Ser 42.6 0.3 1 0 1 AFR 
rs769593006 p.Glu166Gln 45.4 -0.5 1 0 1 NFE 
rs748076875 p.Glu171Val 41.6 -0.1 1 1 1 NFE 
rs754511501 p.Gly173Ser 40.6 -0.4 4 2 1 SAS 
rs779651019 p.Pro178Leu 40.2 -0.1 1 0 1 NFE 
rs758142853 p.Val184Ala 33.1 -0.1 8 1 8 EAS 
rs750052167 p.Leu186Ser 28.7 -0.1 1 0 1 AMR 
- p.Met190Thr 23.6 0.1 1 0 1 SAS 
rs765733397 p.Ala191Pro 24.7 0.0 1 0 1 NFE 
rs762219565 p.Ala193Glu 21.1 0.2 3 0 3 AMR 
rs764661406 p.His195Asn 19.1 -0.1 1 1 1 SAS 
rs764661406 p.His195Tyr 19.1 0.0 1 0 1 NFE 
- p.Glu197Gly 28.0 0.0 2 0 1 ASJ 
- p.Asp198Asn 29.0 -0.7 1 0 1 NFE 
rs750145841 p.Tyr199Cys 28.1 -0.4 4 3 1 AMR 
- p.Tyr199His 28.1 -0.2 1 0 1 SAS 
rs779790336 p.Arg204Thr 28.9 -0.2 1 0 1 SAS 
rs142443432 p.Asp206Gly 22.4 0.0 52 23 50 NFE 
rs754237613 p.Tyr207Cys 26.2 -0.4 1 0 1 NFE 
- p.Val209Ile 25.6 0.0 1 1 1 NFE 
rs148771870 p.Gly211Arg 23.9 -0.3 243 91 165 NFE 
rs761269389 p.Asp216Tyr 27.3 0.2 1 0 1 NFE 
rs753164828 p.Asp216Glu 27.3 -0.1 2 1 2 NFE 
rs372272603 p.Arg219Cys 24.9 -0.2 58 17 52 NFE 
rs759590772 p.Arg219His 24.9 0.0 18 11 17 SAS 
rs774621083 p.Gly220Ser 32.6 -0.1 3 0 1 AFR 
- p.Thr229Ile 37.5 -0.1 1 0 1 NFE 
.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.21.445118doi: bioRxiv preprint 
 
 22 
ID Mutation Distance to Interface mCSM-PPI2 ΔΔG Allele Count AC Male AC Popn. Max Popn. 
Max 
- p.His239Gln 49.7 0.0 1 0 1 NFE 
- p.Ala242Val 50.9 0.4 3 1 3 NFE 
rs771769548 p.Tyr252Cys 47.9 -0.3 2 0 2 NFE 
rs745514718 p.Ser257Asn 56.7 -0.3 1 0 1 EAS 
- p.Ile259Thr 57.2 -0.1 1 0 1 AFR 
rs200745906 p.Pro263Ser 47.8 0.1 9 0 9 NFE 
- p.Gly268Cys 38.9 -0.7 1 0 1 ASJ 
- p.Asp269Glu 36.9 -0.4 0 0 0 
 
rs766319182 p.Met270Val 37.7 -0.1 4 2 4 NFE 
- p.Ser280Tyr 43.8 0.0 1 1 1 NFE 
rs763264372 p.Gln287Arg 49.6 0.0 1 0 1 NFE 
- p.Gln287Lys 49.6 -0.1 1 0 1 AMR 
rs763994205 p.Asn290His 39.9 0.0 2 1 1 SAS 
rs756358940 p.Ile291Lys 36.3 0.0 3 2 3 NFE 
- p.Asp292Asn 35.0 -0.5 1 0 1 NFE 
rs776226831 p.Asp295Gly 34.8 -0.1 7 1 6 NFE 
rs772143709 p.Met297Leu 27.6 -0.3 1 0 1 AFR 
rs745744395 p.Met297Ile 27.6 -0.2 1 1 1 NFE 
rs772143709 p.Met297Val 27.6 -0.1 0 0 0 
 
rs773936807 p.Gln300Arg 29.5 -0.1 2 0 2 NFE 
rs749750821 p.Asp303Asn 22.0 -0.8 2 0 2 SAS 
rs766518362 p.Phe308Leu 17.0 -0.5 1 0 1 NFE 
rs780574871 p.Glu312Lys 12.5 -0.4 3 1 2 AFR 
rs759579097 p.Gly326Glu 5.5 1.0 1 0 1 AFR 
rs143936283 p.Glu329Gly 4.1 -0.4 5 0 4 NFE 
rs185525294 p.Met332Leu 11.2 -0.2 3 2 3 AFR 
rs762357444 p.Gly337Arg 20.2 0.0 1 1 1 NFE 
- p.Asn338Ser 22.9 0.0 3 1 2 AMR 
rs772710779 p.Val339Gly 20.0 -0.2 1 1 1 SAS 
rs138390800 p.Lys341Arg 18.1 0.0 53 10 46 AFR 
- p.Pro346Ser 18.9 0.0 1 1 1 NFE 
rs370610075 p.Gly352Val 5.4 -1.1 2 0 2 NFE 
- p.Asp355Asn 3.5 -1.3 2 0 2 NFE 
- p.Met360Leu 16.0 -0.1 1 1 1 NFE 
rs758568640 p.Met366Thr 28.4 -0.1 2 0 2 NFE 
- p.Asp368Asn 23.6 -0.4 1 0 1 AMR 
- p.His374Arg 20.1 0.0 1 0 1 AMR 
- p.Glu375Asp 16.6 -0.2 3 1 3 AMR 
rs767462182 p.Gly377Glu 17.3 -0.5 1 1 1 NFE 
rs142984500 p.His378Arg 15.3 0.1 15 4 15 NFE 
rs751572714 p.Gln388Leu 6.6 -0.1 4 3 4 AMR 
rs762890235 p.Pro389His 8.1 -0.1 7 2 4 AMR 
- p.Asn397Asp 20.9 -0.1 2 0 2 NFE 
rs772619843 p.Glu398Lys 22.5 -0.4 2 1 2 NFE 
- p.Gly405Glu 22.7 -0.1 1 1 1 NFE 
- p.Lys419Thr 33.1 0.0 1 1 1 EAS 
- p.Ile421Thr 26.4 -0.2 1 1 1 NFE 
- p.Pro426Ala 38.8 0.0 1 0 0 
 
- p.Asp427Tyr 41.7 0.1 2 1 2 AFR 
- p.Gln429Lys 44.4 0.0 1 1 1 SAS 
- p.Asn437His 42.2 0.1 0 0 0 
 
rs764772589 p.Thr445Met 34.1 -0.1 1 1 1 SAS 
rs776328956 p.Val447Phe 38.5 0.9 10 1 4 FIN 
rs763655186 p.Gly448Glu 39.7 -0.6 1 1 1 EAS 
rs760321012 p.Leu450Val 35.9 -0.2 1 0 1 NFE 
rs775744448 p.Met455Ile 39.9 -0.1 1 1 1 SAS 
- p.Trp461Arg 34.1 -0.3 1 0 1 AMR 
rs772445388 p.Val463Ile 37.7 -0.5 1 1 1 SAS 
rs774978137 p.Gly466Trp 37.7 0.0 1 0 1 EAS 
- p.Glu467Lys 40.4 -0.1 4 1 1 AMR 
rs191860450 p.Ile468Val 42.6 -0.5 142 40 138 EAS 
- p.Lys481Asn 42.4 -0.1 0 0 0 
 
rs748359955 p.Arg482Gln 49.3 -0.1 2 1 2 NFE 
rs779752560 p.Glu483Asp 49.2 0.1 7 0 7 AMR 
rs200973492 p.Val488Ala 49.7 0.0 1 0 1 AFR 
rs750415079 p.Val491Met 50.7 -0.4 1 1 1 NFE 
rs765152220 p.Asp494Val 49.7 -0.2 8 3 4 SAS 
rs140473595 p.Ala501Thr 36.2 0.5 2 0 2 NFE 
- p.Phe504Leu 26.3 -0.6 1 0 1 NFE 
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rs760281053 p.Phe504Ile 26.3 -0.3 2 0 2 NFE 
- p.His505Arg 28.6 0.0 1 0 1 EAS 
rs775181355 p.Val506Ala 33.0 0.1 1 1 1 NFE 
rs779199005 p.Tyr510His 23.2 -0.1 0 0 0 
 
rs868506911 p.Arg514Gln 23.4 -0.1 0 0 0 
 
- p.Arg518Thr 27.3 0.4 1 1 1 SAS 
- p.Thr519Ile 30.3 0.0 1 1 1 NFE 
rs759200680 p.Tyr521His 26.7 -0.3 1 0 1 NFE 
rs763593286 p.Ala532Thr 28.5 0.1 10 5 10 SAS 
rs773746588 p.Lys534Arg 32.6 -0.1 1 1 1 NFE 
- p.Pro538Leu 38.7 0.1 1 0 1 SAS 
- p.Lys541Ile 35.8 -0.1 1 0 1 AFR 
rs769821600 p.Ile544Asn 25.7 -0.2 1 0 1 NFE 
rs756905974 p.Asn546Ser 25.3 -0.1 1 0 1 SAS 
rs761944150 p.Asn546Asp 25.3 0.0 4 1 3 AFR 
rs373025684 p.Ser547Cys 24.3 -0.2 43 19 36 NFE 
rs373025684 p.Ser547Phe 24.3 0.0 1 0 1 EAS 
- p.Arg559Ser 11.7 -0.1 1 0 1 AMR 
rs375352455 p.Ser563Leu 15.2 0.1 1 0 1 NFE 
rs750955307 p.Pro565Ser 21.6 0.0 1 1 1 NFE 
- p.Thr567Ala 25.4 0.0 1 0 1 NFE 
- p.Val573Ala 25.4 0.1 2 1 2 EAS 
- p.Val574Ile 28.4 -0.2 1 1 1 SAS 
- p.Gly575Arg 30.3 -0.1 1 0 1 NFE 
rs372924787 p.Arg582Ser 38.7 0.0 1 0 1 AFR 
rs150172355 p.Arg582Lys 38.7 0.0 2 0 2 NFE 
- p.Leu585Pro 39.8 -0.7 1 0 1 EAS 
rs768685219 p.Asn586Tyr 40.9 0.0 1 0 1 FIN 
rs760929786 p.Phe588Ser 38.6 -0.4 1 0 1 AMR 
- p.Glu589Gly 43.9 -0.1 1 0 1 FIN 
rs140857723 p.Thr593Asn 49.6 -0.1 1 0 1 AFR 
rs148036434 p.Leu595Val 47.7 -0.2 2 1 2 NFE 
rs145437639 p.Asp597Glu 54.8 0.0 13 4 11 AFR 
- p.Thr608Ile 53.9 0.0 1 1 1 SAS 
rs747988885 p.Asp609Asn 57.4 0.0 2 1 1 AFR 
rs201715513 p.Ala614Ser 60.5 0.0 35 17 7 FIN 
 





Spike counterparts ARPEGGIO Interaction Types 
S19 3 0.0 A475, G476, S477 Polar-Bond, VdW-Bond, Clash 
Q24 6 0.0 A475, N487, G476, F486, S477, Y489 H-Bond, Clash 
T27 5 0.4 A475, N487, F456, Y473, Y489 VdW-Proximal 
F28 1 0.2 Y489 H-Bond, Polar-Bond 
D30 2 0.7 L455, F456 Hydrophobic-Bond 
K31 6 0.0 Q493, L455, L492, F456, F490, Y489 Hydrophobic-Bond, Clash 
H34 3 0.0 Q493, L455, Y453 Aromatic-Bond, H-Bond, Hydrophobic-Bond, Polar-
Bond, VdW-Bond, Clash 
E35 1 0.0 Q493 H-Bond, Polar-Bond, Clash 
E37 1 0.1 Y505 H-Bond, Hydrophobic-Bond, Polar-Bond 
D38 4 0.0 Q498, G496, HOH701, Y449 H-Bond, Polar-Bond, VdW-Bond, Clash 
Y41 4 0.0 N501, Q498, HOH701, T500 H-Bond, Polar-Bond, VdW-Bond, Clash 
Q42 4 0.0 Q498, HOH701, T446, Y449 VdW-Bond, Clash 
L45 2 0.4 Q498, T500 VdW-Proximal 
L79 2 0.1 G485, F486 Hydrophobic-Bond 
M82 1 0.1 F486 Hydrophobic-Bond, VdW-Bond 
Y83 3 0.0 N487, F486, Y489 Aromatic-Bond, H-Bond, Hydrophobic-Bond, Polar-
Bond, VdW-Bond, Clash 
Q325 2 1.4 R439, V503 VdW-Proximal 
E329 1 1.0 R439 VdW-Proximal 
N330 1 0.3 T500 VdW-Proximal 
K353 7 0.0 N501, Q498, G496, G502, HOH701, F497, 
Y505 
H-Bond, Hydrophobic-Bond, Polar-Bond, VdW-
Bond, Clash 
G354 3 0.2 N501, G502, Y505 Polar-Bond 
D355 2 0.2 G502, T500 VdW-Proximal 
R357 1 0.2 T500 VdW-Proximal 
R393 1 0.5 Y505 VdW-Proximal 
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Spike counterparts ARPEGGIO Interaction Types 
N90-glycan 
(BMA703) 
2 0.1 R408, T415 H-Bond, Polar-Bond, VdW-Bond 
 
 
Supplementary Figure 1. A. Distribution of mCSM-PPI213 predicted ΔΔG from in silico saturation mutagenesis of the ACE2-S 
interface in PDB 6vw111. A. predicted ΔΔG for 475 mutations across 25 sites on ACE2 corresponding to the 23 residues 
within 5 Å of SARS-CoV-2 S plus Gly326 and Gly352. B. predicted ΔΔG for the subset of 151 mutations across these sites that 
are accessible via a single base change of the ACE2 coding sequence. 
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Supplementary Figure 2. Comparison of SPR ΔΔG with the log2 enrichment ratios from the nCoV-S-High sorts from Procko 
and co-workers22. Figure generated with R ggplot2. 
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Supplementary Figure 3. Protein purification size exclusion chromatography and corresponding SDS-PAGE of labelled peaks. 
A. WT RBD, B. WT ACE2, (C) ACE2 mutants E37K and T27R, (continued next page) D. ACE2 mutants G326E and D355N, E. 
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Supplementary Figure 4. Anti ACE2 Antibody (NOVUS AC384-NBP2-80038) binding to WT and 10 ACE2 variants. A. Anti 
ACE2 binding to WT and four ACE2 variants: T27R, G326E, E37K and D355N. B. Binding to WT, S19P and K26R. C. Binding to 
WT, E35K and F40L. D. Binding to WT, E329G and P389H. Anti ACE2 was injected for 600 s association and buffer for a 
further 600 s for dissociation. 
 
Supplementary Figure 5. WT RBD binding WT ACE2 plus equilibrium KD. A. Representative binding trace for WT RBD binding 
immobilised WT ACE2. Injections start from lowest to highest concentration of RBD and fits are shown in blue. B. Plateau 
binding values from A are plotted against the concentration of RBD injected and the equilibrium KD is extracted from the fit 
shown in blue. 
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